Agios Expands Rare Disease Portfolio with Cevidoplenib Deal
Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK)…
Read More...
Read More...
